Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps

L Amaral, M Martins, M Viveiros, J Molnar, Jette E. Kristiansen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Udgivelsesdato: 2008-Sep
OriginalsprogEngelsk
TidsskriftCurrent Drug Targets
Vol/bind9
Udgave nummer9
Sider (fra-til)816-819
Antal sider3
ISSN1389-4501
StatusUdgivet - 1. sep. 2008

Fingeraftryk

Thioridazine
Pumps
Mycobacterium tuberculosis
Pharmaceutical Preparations
Antipsychotic Agents
Bacteria

Citer dette

Amaral, L., Martins, M., Viveiros, M., Molnar, J., & Kristiansen, J. E. (2008). Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. Current Drug Targets, 9(9), 816-819.
Amaral, L ; Martins, M ; Viveiros, M ; Molnar, J ; Kristiansen, Jette E. / Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. I: Current Drug Targets. 2008 ; Bind 9, Nr. 9. s. 816-819.
@article{5bc7d800950d11dda48b000ea68e967b,
title = "Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps",
abstract = "Global rates of pulmonary tuberculosis (TB) continue to increase. Moreover, resistance of the causative organism Mycobacterium tuberculosis to the two most effective anti-TB medications continue to rise. Now, multi-drug resistant TB (MDR-TB) has progressed to extensively drug resistant TB (XDR-TB) - a M. tuberculosis organism that is resistant to the most effective second line drugs available for the treatment of TB. This review provides detailed, significant evidence that supports the use of an old neuroleptic compound, thioridazine (TZ), for the management of MDR-TB and XDR-TB infections and which has been shown to inhibit efflux pumps of bacteria. The argument has been previously presented but no one seems to be listening - and the disease continues unabated when there is a very good probability that the suggested drug will prove to be effective. When the prognosis is poor, available therapy predictably ineffective and death is inevitable, compassionate therapy with TZ should be contemplated. The risks are small and the rewards great.",
author = "L Amaral and M Martins and M Viveiros and J Molnar and Kristiansen, {Jette E.}",
year = "2008",
month = "9",
day = "1",
language = "English",
volume = "9",
pages = "816--819",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers Ltd.",
number = "9",

}

Amaral, L, Martins, M, Viveiros, M, Molnar, J & Kristiansen, JE 2008, 'Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps', Current Drug Targets, bind 9, nr. 9, s. 816-819.

Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. / Amaral, L; Martins, M; Viveiros, M; Molnar, J; Kristiansen, Jette E.

I: Current Drug Targets, Bind 9, Nr. 9, 01.09.2008, s. 816-819.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps

AU - Amaral, L

AU - Martins, M

AU - Viveiros, M

AU - Molnar, J

AU - Kristiansen, Jette E.

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Global rates of pulmonary tuberculosis (TB) continue to increase. Moreover, resistance of the causative organism Mycobacterium tuberculosis to the two most effective anti-TB medications continue to rise. Now, multi-drug resistant TB (MDR-TB) has progressed to extensively drug resistant TB (XDR-TB) - a M. tuberculosis organism that is resistant to the most effective second line drugs available for the treatment of TB. This review provides detailed, significant evidence that supports the use of an old neuroleptic compound, thioridazine (TZ), for the management of MDR-TB and XDR-TB infections and which has been shown to inhibit efflux pumps of bacteria. The argument has been previously presented but no one seems to be listening - and the disease continues unabated when there is a very good probability that the suggested drug will prove to be effective. When the prognosis is poor, available therapy predictably ineffective and death is inevitable, compassionate therapy with TZ should be contemplated. The risks are small and the rewards great.

AB - Global rates of pulmonary tuberculosis (TB) continue to increase. Moreover, resistance of the causative organism Mycobacterium tuberculosis to the two most effective anti-TB medications continue to rise. Now, multi-drug resistant TB (MDR-TB) has progressed to extensively drug resistant TB (XDR-TB) - a M. tuberculosis organism that is resistant to the most effective second line drugs available for the treatment of TB. This review provides detailed, significant evidence that supports the use of an old neuroleptic compound, thioridazine (TZ), for the management of MDR-TB and XDR-TB infections and which has been shown to inhibit efflux pumps of bacteria. The argument has been previously presented but no one seems to be listening - and the disease continues unabated when there is a very good probability that the suggested drug will prove to be effective. When the prognosis is poor, available therapy predictably ineffective and death is inevitable, compassionate therapy with TZ should be contemplated. The risks are small and the rewards great.

M3 - Journal article

C2 - 18781927

VL - 9

SP - 816

EP - 819

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 9

ER -

Amaral L, Martins M, Viveiros M, Molnar J, Kristiansen JE. Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. Current Drug Targets. 2008 sep 1;9(9):816-819.